PD-L1 protein expression in many cancer types, assessed via immunohistochemistry (IHC), is one of the FDA-approved predictive biomarkers for anti-PD-1 and anti-PD-L1 ICI monotherapy [26]. The gene discussed is CD274; the disease is cancer.